Profile data is unavailable for this security.
About the company
USANA Health Sciences, Inc. develops and manufactures nutritional supplements, functional foods, and personal care products. The Company’s product line includes USANA Nutritionals Essentials/CellSentials, optimizers, foods, skincare, and all other. It also manufactures and sells protein bars. It provides a personal development framework that helps individuals create a life of balance, growth, and purpose. Its USANA Nutritionals Essentials/CellSentials includes vitamin and mineral supplements that provides a total body nutrition for every age group beginning with children 13 months of age. Its optimizers include supplements designed to meet individual health and nutritional needs. Its food product line includes meal replacement shakes, snack bars, and other related products that provide macro-nutrition. Its all-other product line includes materials and online tools that are designed to assist its associates in building their businesses and in marketing its products.
- Revenue in USD (TTM)998.60m
- Net income in USD69.35m
- Incorporated1992
- Employees1.90k
- LocationUSANA Health Sciences Inc3838 W Parkway BlvdSALT LAKE CITY 84120-6336United StatesUSA
- Phone+1 (801) 954-7100
- Fax+1 (801) 956-9486
- Websitehttps://www.usana.com/
More ▼
Mergers & acquisitions
| Acquired company | USNA:NYQ since announced | Transaction value |
|---|---|---|
| Oola Global LLC | 18.07% | -- |
| Rise Bar | 18.07% | -- |
Data delayed at least 15 minutes, as of Mar 30 2023 21:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scilex Holding Co | 0.00 | 1.76m | 1.12bn | 2.00 | 60.61 | 1.14 | -- | -- | 0.1272 | 0.1272 | 0.00 | 6.78 | 0.00 | -- | -- | 0.00 | 1.46 | -- | 1.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12,575.16 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 134.04m | -178.93m | 1.13bn | 300.00 | -- | 2.97 | -- | 8.45 | -2.55 | -2.55 | 1.88 | 5.05 | 0.3034 | 0.5057 | 6.23 | 446,786.70 | -40.50 | -44.40 | -51.10 | -50.94 | 93.46 | -- | -133.49 | -349.01 | 4.31 | -- | 0.00 | -- | 39.41 | -- | 40.35 | -- | 15.68 | -- |
| Summit Therapeutics Inc | 705.00k | -78.78m | 1.14bn | 76.00 | -- | 2.72 | -- | 1,613.09 | -0.6299 | -0.6299 | 0.0052 | 0.600 | 0.0018 | -- | 0.7777 | 9,276.32 | -20.26 | -31.37 | -22.09 | -36.78 | -- | -- | -11,174.75 | -391.00 | -- | -7.39 | 0.8024 | -- | -61.03 | -46.51 | 11.08 | -- | -5.36 | -- |
| Avid Bioservices Inc | 140.69m | 116.47m | 1.14bn | 321.00 | 14.13 | 6.13 | 9.23 | 8.09 | 1.29 | 1.29 | 2.01 | 2.97 | 0.368 | 3.34 | 4.97 | 438,295.90 | 30.47 | 12.52 | 38.83 | 17.86 | 21.37 | 19.40 | 82.78 | 26.88 | 0.9991 | 1.65 | 0.4347 | 0.00 | 24.75 | 15.72 | 3,747.86 | -- | 73.13 | -- |
| MoonLake Immunotherapeutics | 0.00 | -64.51m | 1.15bn | -- | -- | 23.55 | -- | -- | -1.88 | -1.88 | 0.00 | 0.9278 | 0.00 | -- | -- | -- | -66.96 | -- | -79.99 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,320.01 | -- | -- | -- |
| Protagonist Therapeutics Inc | 26.58m | -127.39m | 1.15bn | 105.00 | -- | 5.15 | -- | 43.38 | -2.60 | -2.60 | 0.542 | 4.37 | 0.0893 | -- | 12.05 | 253,152.40 | -42.78 | -37.12 | -48.96 | -43.97 | -- | -- | -479.26 | -382.69 | -- | -- | 0.00 | -- | -2.84 | 5.79 | -1.47 | -- | 3.60 | -- |
| Avidity Biosciences Inc | 9.22m | -174.00m | 1.19bn | 186.00 | -- | 2.03 | -- | 128.97 | -3.33 | -3.33 | 0.1769 | 8.29 | 0.0173 | -- | -- | 49,591.40 | -32.63 | -- | -35.34 | -- | -- | -- | -1,886.33 | -- | -- | -- | 0.00 | -- | -1.09 | -- | -47.44 | -- | -- | -- |
| Prime Medicine Inc | 0.00 | -142.01m | 1.19bn | 175.00 | -- | 3.77 | -- | -- | -1.46 | -1.46 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -36.79 | -- | -42.19 | -- | -- | -- | -- | -- | -- | -14.34 | 0.00 | -- | -- | -- | 22.87 | -- | -- | -- |
| Keros Therapeutics Inc | 0.00 | -104.68m | 1.20bn | 105.00 | -- | 4.18 | -- | -- | -4.15 | -4.15 | 0.00 | 10.07 | 0.00 | -- | -- | 0.00 | -37.25 | -- | -39.23 | -- | -- | -- | -- | -- | -- | -114,790.00 | 0.00 | -- | -100.00 | -- | -78.20 | -- | -- | -- |
| USANA Health Sciences, Inc. | 998.60m | 69.35m | 1.21bn | 1.90k | 17.41 | 2.76 | 14.57 | 1.21 | 3.59 | 3.59 | 51.71 | 22.62 | 1.70 | 2.34 | -- | 525,579.50 | 11.81 | 18.87 | 15.95 | 25.68 | 80.58 | 81.88 | 6.94 | 9.65 | 2.21 | -- | 0.00 | 0.00 | -15.83 | -0.9471 | -40.47 | -5.63 | 5.07 | -- |
| Adaptive Biotechnologies Corp | 185.31m | -200.19m | 1.21bn | 790.00 | -- | 2.60 | -- | 6.51 | -1.41 | -1.41 | 1.30 | 3.24 | 0.2082 | 3.44 | 6.45 | 234,567.10 | -22.51 | -17.18 | -25.75 | -19.07 | 68.75 | 70.34 | -108.13 | -115.58 | 4.99 | -1,091.13 | 0.00 | -- | 20.06 | 36.96 | 3.42 | -- | 45.51 | -- |
| Ligand Pharmaceuticals Inc | 196.25m | -5.22m | 1.22bn | 76.00 | -- | 2.03 | 26.33 | 6.21 | -0.3131 | -1.98 | 11.59 | 35.25 | 0.1905 | 2.60 | 3.39 | 2,582,171.00 | -0.5066 | 13.41 | -0.5437 | 14.37 | 73.08 | 84.19 | -2.66 | 79.70 | 2.53 | -- | 0.1138 | -- | -29.19 | 6.82 | -109.13 | -- | 52.74 | -- |
| Dynavax Technologies Corp | 722.68m | 292.87m | 1.23bn | 351.00 | 4.96 | 2.12 | 4.15 | 1.71 | 1.94 | 1.94 | 4.80 | 4.55 | 0.7137 | 4.34 | 5.53 | 2,058,926.00 | 28.95 | -0.6789 | 44.46 | -1.01 | 63.73 | 60.80 | 40.56 | -1.35 | 5.71 | -- | 0.2761 | -- | 64.45 | 366.53 | 305.96 | -- | 60.56 | -- |
| Recursion Pharmaceuticals Inc | 39.84m | -239.48m | 1.23bn | 500.00 | -- | 2.26 | -- | 30.96 | -1.37 | -1.37 | 0.227 | 2.85 | 0.0608 | -- | 2,343.71 | 79,686.00 | -36.52 | -- | -41.12 | -- | -21.16 | -- | -601.05 | -- | -- | -- | 0.0013 | -- | 291.46 | -- | -28.42 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 14.24m | -231.80m | 1.25bn | 389.00 | -- | 1.13 | -- | 87.55 | -4.24 | -4.24 | 0.2599 | 20.00 | 0.0106 | -- | 4.33 | 36,606.68 | -17.32 | -31.51 | -18.15 | -34.42 | 88.03 | -- | -1,627.82 | -1,440.76 | 13.16 | -- | 0.00 | -- | -- | -19.83 | 34.98 | -- | 1.07 | -- |
| Arcus Biosciences Inc | 112.00m | -267.00m | 1.27bn | 500.00 | -- | 1.94 | -- | 11.38 | -3.71 | -3.71 | 1.56 | 9.01 | 0.0763 | -- | 0.2851 | 224,000.00 | -18.18 | -13.06 | -20.72 | -14.82 | -- | -- | -238.39 | -79.12 | -- | -- | 0.00 | -- | -70.75 | 139.78 | -605.39 | -- | 1.70 | -- |
Data as of Mar 30 2023. Currency figures normalised to USANA Health Sciences Inc's reporting currency: US Dollar USD
37.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2022 | 1.76m | 9.17% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 1.50m | 7.84% |
| Renaissance Technologies LLCas of 31 Dec 2022 | 1.22m | 6.38% |
| Pzena Investment Management LLCas of 31 Dec 2022 | 716.88k | 3.73% |
| Dimensional Fund Advisors LPas of 31 Dec 2022 | 551.48k | 2.87% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 425.28k | 2.21% |
| Acadian Asset Management LLCas of 31 Dec 2022 | 368.32k | 1.92% |
| Geode Capital Management LLCas of 31 Dec 2022 | 225.96k | 1.18% |
| Invesco Capital Management LLCas of 31 Dec 2022 | 192.65k | 1.00% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2022 | 189.44k | 0.99% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
